Haematological malignancies: at the forefront of immunotherapeutic innovation
Open accessThe DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Abstract
The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Cited by
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Self-citationThe interaction of innate immune and adaptive immune system
Wang, R., Lan, C., Benlagha, K., Camara, N. O. S., Miller, H., Kubo, M., Heegaard, S., Lee, P., Yang, L., Forsman, H., et al. (2024) · MedComm · doi:10.1002/mco2.714 · Cited by 305
“168 In the innate immune system, tumor-associated macrophages (TAMs) play an important role in tumor suppression.”
BackgroundThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
“Growing knowledge about tumor and immune cell biology led to continuous development of immunotherapies against each of the four major nodes of vulnerability in the cancer–immune relationship: direct targeting of surface antigens; boosting of numbers and functioning of immune effectors; activating tumor antigen-specifi…”
BackgroundImmunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei, J., Yang, Y., Wang, G., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035276 · Cited by 183
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
“19 HSCT refers to the transplantation of hematopoietic stem cells from a donor into a recipient to rebuild or restore the recipient ’ s immune system.”
BackgroundGenomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 148
“From the standpoint of therapy, the presence of intratumoral heterogeneity strongly supports on one hand personalized therapies, and on the other hand, the use of therapies that can target multiple vulnerable nodes simultaneously—whether this is through combination therapy, that can include chemotherapy and/or combine…”
BackgroundSelf-citationHarnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 120
“malignancies providing encouragement for their use in the treatment of AML [195, 196].”
Immunotherapy in hematologic malignancies: past, present, and future
Im, A., & Pavletic, S. Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0453-8 · Cited by 108
“Although immunotherapy has shown success in a wide variety of cancers including many solid tumors, there are some unique features of hematologic malignancies in this setting that makes these cancers well poised as targets of immunotherapy [15].”
BackgroundIL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update
Oliveira, M. L., Akkapeddi, P., Ribeiro, D., Melão, A., & Barata, J. T. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.09.012 · Cited by 106
Zamora, A. E., Crawford, J. C., Allen, E. K., Guo, X.-Z. J., Bakke, J., Carter, R. A., Abdelsamed, H. A., Moustaki, A., Li, Y., Chang, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8549 · Cited by 100
“We hypothesized that although pediatric leukemias contain lower mutational burdens, the neoantigens that arise in this tumor type likely serve as functional targets due to their increased immunogenicity resulting from the tumor’s microenvironment, cellular origin, and high neoepitope expression (34).”
BackgroundLeukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 102
Anticancer Potential of Sanguinarine for Various Human Malignancies
Achkar, I. W., Mraiche, F., Mohammad, R. M., & Shahab Uddin, M. S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0041 · Cited by 72
Myeloid-derived suppressor cells in B cell malignancies
Yazdani, Y., Mohammadnia‐Afrouzi, M., Yousefi, M., Anvari, E., Ghalamfarsa, G., Hassannia, H., Sadreddini, S., & Jadidi‐Niaragh, F. (2015) · Tumor Biology · doi:10.1007/s13277-015-4004-z · Cited by 58
Okoye, I., Xu, L., Walker, J. W. T., & Elahi, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02555-2 · Cited by 61
Specifically differentiated T cell subset promotes tumor immunity over fatal immunity
Ramadan, A. M., Griesenauer, B., Adom, D., Kapur, R., Hanenberg, H., Liu, C., Kaplan, M. H., & Paczesny, S. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170041 · Cited by 57
Escobar, G., Barbarossa, L., Barbiera, G., Norelli, M., Genua, M., Ranghetti, A., Plati, T., Camisa, B., Brombin, C., Cittaro, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05315-0 · Cited by 55
Bledsoe, J. R., Redd, R. A., Hasserjian, R. P., Soumerai, J. D., Nishino, H., Boyer, D. F., Ferry, J. A., Zukerberg, L. R., Harris, N. L., Abramson, J. S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24485 · Cited by 53
Antigen Loss Variants: Catching Hold of Escaping Foes
Vyas, M., Müller, R., & von Strandmann, E. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00175 · Cited by 47
“The most promising immunotherapeutic options for leukemia include targeted approaches such as chimeric antigen receptor (CAR) modified T cells (CAR-T cells) and antibody-based therapies that activate T and NK cells (11).”
BackgroundSeo, S., Hong, J. Y., Yoon, S., Yoo, C., Park, J. H., Lee, J. B., Park, C.-S., Huh, J., Lee, Y. S., Kim, K. W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12734 · Cited by 51
Cieri, N., Maurer, K., & Wu, C. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0301 · Cited by 49
Self-citationTumour flare reaction in cancer treatments: a comprehensive literature review
Amina Taleb, B. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000814 · Cited by 41
Liu, Y., Hu, Y., Gu, F., Liang, J., Zeng, Y., Hong, X., Zhang, K., & Liu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18771 · Cited by 40
“Immunotherapy is a promising option and has showed attractive benefits in hematological neoplasms [2].”
Background'Trained immunity: consequences for lymphoid malignancies
Stevens, W. B. C., Netea, M. G., Kater, A. P., & van der Velden, W. J. F. M. (2016) · Haematologica · doi:10.3324/haematol.2016.149252 · Cited by 40
Folci, M., Ramponi, G., Shiffer, D., Zumbo, A., Agosti, M., & Brunetta, E. (2019) · Journal of Immunology Research · doi:10.1155/2019/1732175 · Cited by 36
“Regarding PR3, it is important to note that along with being GPA’s main autoantigen, it is also overexpressed in several HM such as acute and chronic myeloid leukemia cell lines [54, 55].”
BackgroundGromek, S. M., deMayo, J. A., Maxwell, A. T., West, A. M., Pavlik, C. M., Zhao, Z., Li, J., Wiemer, A. J., Zweifach, A., & Balunas, M. J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.040 · Cited by 30
Recent advances in T‐cell immunotherapy for haematological malignancies
Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 26
“Additionally, with the availability of sophisticated genomic and proteomic techniques tumour-specific neoantigens can be detected (Bachireddy et al, 2015).”
BackgroundJiang, X., Chen, X., Jaiprasart, P., Carpenter, T. J., Zhou, R. Z., & Wang, W. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105260 · Cited by 27
ADARs, RNA editing and more in hematological malignancies
Teoh, P. J., Koh, M. Y., & Chng, W. J. (2020) · Leukemia · doi:10.1038/s41375-020-01076-2 · Cited by 30
Bachireddy, P., Ennis, C. S., Nguyen, V. N., Gohil, S. H., Clement, K., Shukla, S. A., Forman, J., Barkas, N., Freeman, S. S., Bavli, N. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7661 · Cited by 25
Self-citationLee, K.-J., Choi, D., Tae, N., Song, H. W., Kang, Y., Lee, M., Moon, D., Oh, Y., Park, S., Kim, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101567 · Cited by 29
Antigen-specific immunotherapies for acute myeloid leukemia
Buckley, S. A., & Walter, R. B. (2015) · Hematology · doi:10.1182/asheducation-2015.1.584 · Cited by 23
SLAMF6 in health and disease: Implications for therapeutic targeting
Yigit, B., Wang, N., Herzog, R. W., & Terhorst, C. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.013 · Cited by 25
“Malignant cells arise from blood cells of common lymphoid and myeloid progenitor origin and are categorized under three main subsets: leukemias (acute and chronic), lymphomas and myelomas [113].”
BackgroundZhao, T., Ren, H., Wang, X., Liu, P., Fan, Y. L., Jiang, W., Li, Y., Li, J., Gribben, J. G., Jia, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4816 · Cited by 24
“There is accumulating evidence for the hypothesis that long-term clinical success of anticancer therapy requires the participation of immune responses to ‘danger’ signals emitted by cancer cells [42, 43].”
BackgroundImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Freeman, C. L., & Gribben, J. G. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0295-9 · Cited by 28
“Haemato-oncology has been at the forefront of immunotherapeutic innovation for decades, and CLL is a condition that lends itself extremely well to the investigation of various immune interventions with readily accessible tissue from both malignant and infiltrating immune cells [2••]. Curr Hematol Malig Rep (2016) 11:2…”
BackgroundInfluentialZuo, B., Yan, B., Zheng, G., Xi, W., Zhang, X., Yang, A., & Jia, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2089-5 · Cited by 26
“, CD19 and CD20, the inadequate tumor specificity of targeted antigens has frequently led to the immune toxicity and off-target effects of CAR-T cells [15, 16].”
BackgroundNitric Oxide in Hematological Cancers: Partner or Rival?
Vivarelli, S., Falzone, L., Basile, M. S., Candido, S., & Libra, M. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7958 · Cited by 24
Mathoulin‐Pélissier, S., & Pritchard‐Jones, K. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.02.015 · Cited by 23
Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis
Folci, M., Ramponi, G., Solitano, V., & Brunetta, E. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08887-w · Cited by 24
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting
Sun, X., Yu, Y., Ma, L., Xue, X., Gao, Z., Ma, J., & Zhang, M. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00819-y · Cited by 16
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions
Tawfik, E. A., Aldrak, N. A., Albrahim, S. H., Alzahrani, D. A., Alfassam, H. A., Alkoblan, S. M., Almalik, A., Chen, K., Abou-Khalil, R., Shah, K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0065 · Cited by 20
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting
Penter, L., & Wu, C. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129209 · Cited by 19
“The blood malignancies have been consistently at the forefront of targeted cellular therapy and combinatorial immune-based treatment approaches (13).”
BackgroundSelf-citationGut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy
Cheng, P., Shen, P., Shan, Y., Yu, Y., Deng, R., Chen, W., Lu, Y., & Wei, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626045 · Cited by 17
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 17
“Hematological malignancies, in particular, possess distinctive characteristics that make them especially amenable to immunotherapy [16].”
HER3 receptor and its role in the therapeutic management of metastatic breast cancer
Zhu, M., Yu, M., Meng, Y., Yang, J., Wang, X., Li, L., Liang, Y., & Kong, F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05445-8 · Cited by 22
“Endogenous ligands of tumor antigens may be more suit - able than single-chain variable fragments as components of chimeric antigen receptors, with high cancer-recogni-tion potential and minimal immunogenicity [131, 132].”
BackgroundCellular immunotherapy as a beacon of hope for hematological malignancies
Lee, H.-J., Kim, S.-K., Cho, D., & Lee, J. (2015) · Blood Research · doi:10.5045/br.2015.50.3.126 · Cited by 12
“Indeed, the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) largely derives from graft-versus-tumor effects that highlight the ability of the immune system to specifically and effectively eliminate tumors [1].”
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies
Braun, D. A., & Wu, C. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000257 · Cited by 14
Self-citationThe end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia
Nagler, A., & Wu, C. J. (2022) · Blood · doi:10.1182/blood.2021014669 · Cited by 10
Self-citationTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
Savona, M. R., Sochacki, A. L., & Fischer, M. A. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s83868 · Cited by 11
“Additionally, different mechanisms of vaccine delivery are being examined, including costimulation with cytokines like GM-CSF, or the administration of the antitumor vaccines post-allo-HSCT when there is a greater chance for a graft-vs-leukemia response.(127,128) Continued investigation in these areas will likely eluc…”
Bansal, A. K., Sharawat, S. K., Gupta, R., Vishnubhatla, S., Dhawan, D., & Bakhshi, S. (2020) · PubMed Central · Cited by 9
Li, Q., Pan, H., Gao, Z., Li, W., Zhang, L., Zhao, J., Fang, L., Chu, Y., Yuan, W., & Shi, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1063227 · Cited by 11
“Instead of activating functional effector T cells, UNC93B tended to recruit regulatory T cells, which were responsible for the initiation and development of acute and chronic leukemia (Moon et al., 2011; Bachireddy et al., 2015; Wan et al., 2020), and mediated immune escape of myeloblast in de novo AML (Wan et al.”
BackgroundOlivares-Hernández, A., Figuero-Pérez, L., Terán‐Brage, E., López-Gutiérrez, Á., Tamayo-Velasco, Á., González‐Sarmiento, R., Cruz, J. J., & Miramontes‐González, J. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091919 · Cited by 9
“Finally, it is also important to note that many haematologic malignancies have a low mutation load and are therefore less immunogenic than many solid tumours [79].”
BackgroundThe Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy
Hardy, M., Vincent, K., & Perreault, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02934 · Cited by 9
“Another mTSA derived from a BCR-ABL fusion protein was identified via MS analyses in 2001 (37), but was not found in a larger cohort of subjects in 2019 (38), and its immunogenicity was called into question (39).”
BackgroundTargeting collagen in “armored and cold” tumors: Overcoming barriers to cancer therapy
Wang, S., Li, J., & Zhao, Y. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.11.001 · Cited by 7
“8 Moreover, immunotherapies often result in organ-speci fi c in fl ammatory side effects, known as immune-related adverse events (irAEs).”
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
Ebinama, U., & George, B. (2025) · Discover Oncology · doi:10.1007/s12672-025-01797-9 · Cited by 8
The role of epigenetic modifications in hematological cancers
Ilic, J., Bold, A., & Knop, S. T. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744018 · Cited by 4
“Overexpression of MMSET in patients with t (4, 14) translocations (110).”
Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies
Gezici, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00035-4 · Cited by 6
Incorporating mRNA therapeutics into biological treatments of hematologic malignancies
Hunia, J., Tomasik, J., Czerwik, N., Pezeshki, P. S., & Nowis, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680071 · Cited by 6
Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms
Pemmaraju, N., Chen, N. C., & Verstovšek, S. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.007 · Cited by 4
Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Banerjee, S., Amin, S. A., & Jha, T. (2021) · Current Chemical Biology · doi:10.2174/2212796815666210203104446 · Cited by 4
Chen, Z., Cheng, Y., DeRemer, D. L., & Diaby, V. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1913056 · Cited by 4
Ipe, A., Fermaglich, L. J., Kraft, S., Mease, C., Le, T., & Miller, K. L. (2024) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2024.2333245 · Cited by 4
“First, hematologic cancers may have higher approval rates because of the success of drug cocktails in improving outcomes for specific subgroups [29].”
Paczesny, S. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.8 · Cited by 3
The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study
Hashem, J., Alsukhni, F., Abushukair, H. M., & Ayesh, M. H. (2024) · Biomolecules · doi:10.3390/biom14121559 · Cited by 2
Mendiola-Soto, D. K., Gómez-Romero, L., Núñez-Enríquez, J. C., Flores‐Lujano, J., Jiménez‐Hernández, E., Medina‐Sansón, A., Méndez, V. C. B., Mata‐Rocha, M., Pérez‐Saldívar, M. L., Duarte-Rodríguez, D. A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091405 · Cited by 1
“Nevertheless, the immune responsiveness in allogenic hematopoietic stem cell transplantation and in immunotherapy for relapsed or refractory ALL set the basis to hypothesize that leukemic cells could express new immunogenic specific peptides [22].”
Jin, Y., Lu, H.-M., Yu, X., Su, M.-Z., Li, J., Li, X.-M., Jin, J., Zhang, L.-T., & Wang, Y. (2026) · Mediators of Inflammation · doi:10.1155/mi/2476470 · Cited by 1
Ascierto, P. A., Cartenì, G., Gridelli, C., Pignata, S., Pinto, A., Criscitiello, C., Buonaguro, L., Pepe, S., Mabilia, R., Montesarchio, V., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0144-y · Cited by 1
“Lymphomas Application of immunotherapy to the management of lymphomas poses unique challenges and opportunities since these malignancies originate from the immune system itself [49].”
BackgroundSelection and Monitoring of Patients for Immunotherapy (Peptide Vaccines)
Liu, X., & Kline, J. P. (2015) · Springer eBooks · doi:10.1007/978-4-431-55726-5_4 · Cited by 2
Hematopoietic Stem Cell Transplantation for Malignant Diseases
Munshi, P. N., Rowley, S. D., & Korngold, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00092-7 · Cited by 1
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition
Khan, M., Sarfraz, M., & Daver, N. G. (2016) · Future Oncology · doi:10.2217/fon-2016-0310
Hematopoietic Stem Cell Transplantation for Malignant Diseases
Munshi, P. N., Rowley, S. D., & Korngold, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00083-1
Immunotherapy in Hematological Malignancy
Ayağ, H., Ertop, Ş., Ak, M. A., & Sahip, B. (2024) · doi:10.69860/nobel.9786053359388.4
Valenzano, G., Russell, S. N., Go, S., O’Neill, E., & Jones, K. I. (2024) · Current Protocols · doi:10.1002/cpz1.70032 · Cited by 2
“While immunotherapy has achieved remarkable success in hematological malignancies (Bachireddy et al., 2015; Kalos et al., 2011; Kantarjian et al., 2017; Kochenderfer et al., 2010; Tang et al., 2023), its efficacy in solid tumors, aside from highly immunogenic types such as melanoma (Knight et al.,…”
ASXL1 truncating mutations drive leukemic resistance to T cell attackPreprint
McCurry, D., Ge, Z., Lee, J., Pasumarthi, R., Leng, X., Köhnke, T., Pasvolsky, O., Raparla, P., Nguyen, V. N., Maurer, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.29.656798 · Cited by 1
Self-citationKaur, K., & Jewett, A. (2025) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2025060671
Pfister, S. K., Seehusen, F., Prisco, F., Rotta, G., Elsayed, A., Gilardoni, E., Thorhallsdottir, G., Pellegrino, C. E., Manz, M. G., Puca, E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0340
Vatansever, A. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111429
Flow cytometry evaluation of cytotoxicity exerted by effector immune cells against tumor cells
Ripollés-Yuba, C., Giraldos, D., Galano-Frutos, E., Reina-Ortiz, C., & Anel, A. (2026) · Methods in cell biology · doi:10.1016/bs.mcb.2026.02.008
Etude des facteurs de chimiorésistance de la leucémie lymphoïde chronique
Guièze, R. (2017) · theses.fr (ABES) · doi:10.70675/d280d332z0fd1z4715z88daz141b23dbc8e5
Immunotherapy in pancreatic cancer: overcoming the challenges of tumor heterogeneity
Nakamura, M., He, Z., Dhulia, R., Manji, G. A., & Reya, T. (2026) · Trends Open · doi:10.1016/j.treopn.2026.04.001 · Cited by 1
Bose, C. K. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1824552
Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies
Mathias, F., Fersing, C., Bourgarel‐Rey, V., Gabert, J. A., & Peyron, F. (2026) · Cells · doi:10.3390/cells15161439
“Hematologic malignancies have some unique characteristics as accessibility of malignant cells (circulating or marrow-based) and well-characterized antigenic targets (e.g., CD19, CD20, BCMA) that make these cancers well-suited as targets for immunotherapy [3].”
Metadata
- Authors
- Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Wu, Catherine J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-03-19
- Volume
- 15
- Issue
- 4
- Pages
- 201-215
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4511812
- OpenAlex
- W2083691419
- Cited by
- 85
- References
- 215
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 11 · 2016: 11 · 2015: 7
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL103532)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (P01CA206978, R01CA155010, T32CA009172, P30CA006516)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- hematologic malignancies, cancer immunotherapy, immune evasion, cancer immune response, immune checkpoint inhibitors, adoptive immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Hematologic Neoplasms, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.